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INTRODUCTION
Whole-exome sequencing (WES) has emerged as a successful 
diagnostic tool in the study of genetic disease and has proven 
to be particularly effective in identifying disease-associated 
genes that are refractory to linkage analysis. Furthermore, WES 
has shown diagnostic utility in routine clinical settings. One 
recent exome sequencing study reported a diagnostic rate of 
25% in a heterogeneous population of 250 patients,1 whereas 
other studies have reported variable, sometimes higher, rates.2–4 
However, a limitation of most current studies, and indeed clini-
cal analyses, is that a diagnosis is only possible if the gene has 
been previously implicated in a similar condition. The immense 
value that WES offers in identifying novel disease genes often 
remains unexplored.
In this study, we applied trio WES (i.e., sequencing the patient 
and both unaffected biological parents) to a cohort of 119 
patients who had been referred to medical geneticists for a vari-
ety of conditions. They comprise 113 trios reported for the first 
time and 6 previously unresolved trios2 that are reinterpreted. 
Importantly, this cohort of patients reflects a heterogeneous 
collection of clinical presentations, making the cohort repre-
sentative of a typical genetics clinic. Through trio sequencing, 
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Purpose: Despite the recognized clinical value of exome-based diag-
nostics, methods for comprehensive genomic interpretation remain 
immature. Diagnoses are based on known or presumed patho-
genic variants in genes already associated with a similar phenotype. 
Here, we extend this paradigm by evaluating novel bioinformatics 
approaches to aid identification of new gene–disease associations.
Methods: We analyzed 119 trios to identify both diagnostic geno-
types in known genes and candidate genotypes in novel genes. We 
considered qualifying genotypes based on their population frequency 
and in silico predicted effects we also characterized the patterns of 
genotypes enriched among this collection of patients.
Results: We obtained a genetic diagnosis for 29 (24%) of our 
patients. We showed that patients carried an excess of damaging de 
novo mutations in intolerant genes, particularly those shown to be 
essential in mice (P = 3.4 × 10−8). This enrichment is only partially 
explained by mutations found in known disease-causing genes.
Conclusion: This work indicates that the application of appropri-
ate bioinformatics analyses to clinical sequence data can also help 
implicate novel disease genes and suggest expanded phenotypes for 
known disease genes. These analyses further suggest that some cases 
resolved by whole-exome sequencing will have direct therapeutic 
implications.
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we identify qualifying genotypes, focusing on genotypes seen 
only in the patient and not in unaffected parents or controls.2 
This approach not only provides diagnoses based on mutations 
found in already known genes but also can provide pointers 
toward novel disease genes, such as the identification of NGLY1 
in our previous work,2 which was subsequently confirmed in 
seven additional rare cases with similar clinical presentations.5 
We expect such examples will emerge more frequently as care-
ful bioinformatics analysis of candidates becomes a central part 
of diagnosing genetic disease.6
MATeRIALs AND MeTHODs
subjects
A total of 113 patients with suspected genetic disorders, and 
their unaffected biological parents, are reported here for the 
first time. In general, the clinical presentations of most patients 
were considered severe (Supplementary Table S1 online), and 
the patients were either judged to have an undiagnosed genetic 
disorder or suspected to have a specific genetic disorder that 
was genetically unresolved based on known diagnostic panels. 
Sixty-five trios were recruited at the Genome Sequencing Clinic 
at Duke University Medical Center, and 48 were recruited at the 
pediatric clinic of the Sheba Medical Center in Tel HaShomer, 
Israel. Clinical phenotypes are shown in Supplementary 
Table S1 online. We previously published an analysis of 12 pilot 
trios recruited in a similar way at Duke.2 Here, we reinterpret 
six trios that were unresolved in those analyses.2 A total of 119 
trios are reported.
All 119 patients underwent a clinical genetics evaluation, with 
traditional genetic diagnostics performed whenever clinically 
indicated. All patients reported here remained undiagnosed 
or unresolved after tests including candidate mutation and/or 
gene testing, karyotyping, chromosomal microarray analysis, 
and gene panels. The appropriate institutional review boards 
approved this research protocol. Written informed consent was 
received from all participants or their guardians.
To estimate the population frequency of both variants and 
genotypes, we used two independent sources of population con-
trol data, totaling up to 9,530 individuals. The internal control 
cohort comprised subjects enrolled in the Center for Human 
Genome Variation through Duke institutional review board–
approved protocols (n = 3,027). Among these controls, 83.5% 
were Caucasian, 6.7% were Middle Eastern, 3.5% were African, 
and the remaining 6.3% were of Asian or other ancestries. 
Although these internal controls were not ascertained for rare 
disorders, their individual phenotypes were not analyzed and 
some could have rare pathogenic variants. The external control 
cohort comprises subjects enrolled in the National Heart, Lung, 
and Blood Institute Grand Opportunity Exome Sequencing 
Project (n = 6,503, http://evs.gs.washington.edu/EVS/).
sequencing and bioinformatics pipeline
DNA was extracted from a peripheral blood sample. To capture 
the coding regions, we used the 65-Mb Illumina TruSeq Exome 
Enrichment Kit (Illumina, San Diego, CA), the 64-Mb Roche 
NimbleGen SeqCap EZ Exome Library Kit (Roche NimbleGen, 
Madison, WI), or the 50-Mb Agilent SureSelect Human All 
Exon Kit (Agilent, Santa Clara, CA). The capture kit type was 
consistent within a given trio. All sequencing was performed on 
the Illumina HiSeq 2000 platform (Illumina) at the Genomic 
Analysis Facility in the Center for Human Genome Variation. 
The overall coverage statistics for each individual are shown in 
Supplementary Table S2 online.
Using Burrows-Wheeler Aligner (BWA-0.5.10),7 sequenc-
ing reads were mapped to a Genome Reference Consortium 
Human Genome Build 37 (GRCh37)-derived alignment set 
including decoy sequences; the same reference genome is 
used in the 1000 Genomes Project (http://www.1000genomes.
org/). Polymerase chain reaction duplicates were removed 
using picard-tools-1.59 (http://picard.sourceforge.net). 
Single-nucleotide variants and small insertions/deletions 
(indels) were called using the UnifiedGenotyper of the 
Genome Analysis Toolkit (GATK-1.6–11)8 and annotated 
using SnpEff-3.3 (Ensembl 73 database).9 The six revisited 
trios were also subjected to this bioinformatics pipeline; pre-
viously, they were aligned to GRCh36 and variants were called 
using SAMtools.10
Identifying qualifying genotypes
For each patient, we hypothesized that completely penetrant 
genotypes would explain the major clinical manifestations. 
Using the trio WES data along with in silico and population 
site frequency data of genetic variants, we generated a list of 
“qualifying genotypes” for each trio. Each variant had to meet 
specific quality control thresholds (Supplementary Method 
1.1 online). In terms of functional annotation, we included 
only protein-altering variants, including truncating vari-
ants (stop gain/loss, start loss, or frameshift), missense vari-
ants, canonical splice-site variants, inframe indels affecting 
protein-coding regions, and variants within the intron–exon 
boundary (eight bases flanking the exonic boundaries). We 
primarily focused on genotypes absent in control data sets. 
We systematically considered four different genetic models, 
using stratified European and African Americans in the Exon 
Variant Server (EVS) for minor allele frequency estimations: 
(i) germ-line de novo mutations, also absent in the available 
control populations (extended to include mitochondrial DNA 
sequence by requiring mother to have only the reference allele 
while the patient has only the mutant allele); (ii) recessive 
homozygous genotypes, which were heterozygous in both 
parents, never homozygous in controls, with a control allele 
frequency <1%; (iii) hemizygous X chromosome variants 
inherited from an unaffected heterozygous mother, with a 
control allele frequency <1% and never observed in male con-
trols or homozygous in female controls; and (iv) compound 
heterozygous genotypes in the patient (one variant inherited 
from each heterozygous parent, with the two variants occur-
ring at different genomic positions within the same gene), for 
which neither variant was ever homozygous in controls, and 
each had a control allele frequency <1%. For the compound 
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heterozygous genotypes, we further required that regardless 
of phasing, the two variants never co-occurred in the Center 
for Human Genome Variation controls. Genotypes meeting 
these criteria were referred to as “qualifying genotypes,” with 
the genes harboring qualifying genotypes referred to as “qual-
ifying genes.” 
Determination of genetic diagnosis
For each trio, the list of qualifying genes was checked against 
OMIM. Specifically, we required that (i) the OMIM disease 
phenotype overlapped the patient’s clinical features; (ii) the 
qualifying genotype was consistent with the reported OMIM 
inheritance pattern (e.g., dominant or recessive); and (iii) the 
qualifying mutation itself was reported in a similarly affected 
patient or the qualifying mutation was of the same functional 
class (e.g., loss-of-function, missense) as those reported in a 
similarly affected patient. The genetics team then communi-
cated directly with the treating clinicians to discuss whether 
a relevant qualifying genotype could explain the clinical pre-
sentation of the patient. When both the genetics team and the 
treating clinicians agreed that the qualifying genotype was the 
final diagnosis, the qualifying genotype was considered to be 
a “genetic diagnosis” (Supplementary Table S6 online). We 
referred to cases assigned a diagnosis in this way as “resolved.” 
Each of the variants leading to a diagnosis was visually 
inspected using Integrative Genomics Viewer11 followed by 
Sanger validation. These Sanger validations were performed 
at the Center for Human Genome Variation for trios recruited 
from Sheba and by a CLIA-certified laboratory for trios 
recruited from Duke.
For trios without a genetic diagnosis determined (unre-
solved), and with a sufficiently small number of qualifying 
genotypes, we performed a broader literature inspection to 
highlight potentially interesting candidates to be followed up in 
future studies (Supplementary Method 2 online).
Bioinformatic signatures of causal variants
Among the 103 patients who did not have a genetic diagno-
sis determined by an inherited genotype, we used a previously 
described gene-level and variant-level prioritization framework 
to interpret the properties of their de novo mutations in com-
parison with control trio de novo mutations.12 For the gene-level 
score, we used the Residual Variation Intolerance Score scor-
ing system introduced by Petrovski et al.12 For the variant-level 
score, we took the Ensembl PolyPhen-2 HumVar scores13 for 
missense de novo mutations and assigned nonsense and canon-
ical splice-site mutations a score of 1. Synonymous mutations 
were assigned a score of 0. We prioritized de novo mutations 
that reside in the “hot zone” previously defined by Petrovski et 
al.12 by a Residual Variation Intolerance Score percentile score 
(y-axis) ≤0.25 and a PolyPhen-2 score (x-axis) ≥0.95. We used 
data from 728 published control trio subjects;14–19 337 controls 
had at least one assessable de novo mutation to estimate the 
empirical distribution of the gene-level and variant-level scores 
in the 2D space, particularly the expected proportion of de 
novo mutations within the hot zone (Supplementary Method 
1.2 online).
We subsequently incorporated new information about 
essential mouse genes as extracted from the Mouse Genome 
Database by Georgi et al..20 A correlation had been previously 
established between essential mouse genes and genes that 
are intolerant to functional variation in the human popula-
tion (Residual Variation Intolerance Score; P = 1.3 × 10−114) 
(Table 1 of Petrovski et al.12). Despite this correlation, we 
wanted to assess whether integrating intolerant scores with 
the essential gene list would create a stronger signature of 
pathogenic mutations. We therefore assessed the value of 
taking the intersection between de novo hot zone mutations 
and 2,472 essential genes—human orthologs of genes that 
result in lethality when either or both copies are disrupted 
in mice.20,21
ResULTs
Genetic diagnosis based on known gene–disease 
associations
On average, 94.2% of the exome-wide consensus coding 
sequence (CCDS) sequence (release 14) was covered with at 
least 10-fold coverage (Supplementary Table S2 online). We 
identified an average of 12 qualifying genotypes for each trio, 
averaging one de novo, one newly hemizygous, three newly 
homozygous, and seven compound heterozygous genotypes 
(Supplementary Table S3 online). Compared with Duke trios 
(n = 71), Sheba trios (n = 48) had, on average, more newly 
homozygous qualifying genotypes (Supplementary Table S3 
online); this is consistent with the higher percentage of con-
sanguinity among Sheba trios (18.8 vs. 1.4% among Duke trios; 
Supplementary Table S1 online). Sheba trios also had more 
qualifying genotypes than Duke trios (Supplementary Table S3 
online), consistent with the fact that our control cohorts (com-
prising primarily Caucasians) are more ethnically matched with 
Duke trios than with Sheba trios (Middle Eastern origin).
Discussion with the treating physicians followed by Sanger 
validation established the diagnoses for a total of 29 patients 
(Supplementary Table S6 online). Thirteen (45%) were due to 
a de novo mutation, seven (24%) were due to a newly homo-
zygous genotype, five (17%) were due to a newly hemizygous 
genotype, and four (14%) were due to a compound hetero-
zygous genotype. The percentage of cases diagnosed with 
recessive conditions is higher than that reported in previous 
studies,1 presumably due to the increased level of consan-
guinity in the Israeli cohort as compared with the popula-
tions in most other published WES diagnostic studies.
We have four examples in which the genetic diagnosis led 
to an immediate change in management. For two of the four 
patients, the genetic diagnoses informed specific pharmaco-
therapies. These patients are the patient of trio 10, who has a 
de novo missense mutation in KCNQ2 (Supplementary Table 
S6 online) and has been prescribed retigabine,22 and the patient 
of trio 53, who has a de novo missense mutation in KCNT1 
(Supplementary Table S6 online) and has been treated with 
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quinidine.23 Retigabine treatment has reduced seizure fre-
quency in the first patient (trio 10) despite a lack of an observ-
able positive effect on development. In two additional patients 
(trio 24 and trio 26), the genetic diagnoses led to specific diet 
interventions that significantly improved the patients’ meta-
bolic conditions.
Identifying novel disease genes: bioinformatic signatures 
can point toward novel genes
Prioritizing based on genic intolerance12 highlights the clear 
presence of hot zone de novo mutations among our clinically 
heterogeneous collection of 103 patients unresolved by a reces-
sive genotype. Seventy patients had at least one assessable de 
novo mutation, and 29 (41.4%) of these resided in the hot zone 
(Supplementary Table S7 online). This is compared with the fre-
quency of hot zone de novo mutations among control trios with 
13.1% (44/337) of controls with at least one assessable de novo 
mutation (P = 2.3 × 10–7, Fisher’s exact test; Figure 1). Similar to 
the previous publications of this approach in specific neuropsy-
chiatric ascertainments,12,24 this indicates that presence of a hot 
zone de novo mutation is a strong candidate even among our 
heterogeneous collection of rare disorders. Considering the 103 
patients unresolved by a recessive disorder, 28.2% of the patients 
had a hot zone de novo mutation as compared with 6.0% among 
the 728 sequenced control trios (P = 3.0 × 10−10; Figure 1).
We also found that de novo mutations occurring in the essen-
tial genes were enriched among patients as compared with 
controls (31.1% (32/103) vs. 11.5% (84/728); P = 1.1 × 10−6). 
Moreover, we found that de novo hot zone mutations in essential 
genes occurred in 16 (15.5%) of the 103 case trios and in only 
14 of the 728 control trios (1.9%) (P = 3.4 × 10–8, Fisher’s exact 
test). This translates to ~88% (14/16) of the patients having been 
directly ascertained for such hot zone de novo mutations among 
essential genes (Figure 1 and Supplementary Table S7 online), 
and it strongly suggests that in the majority of the patients with 
such a mutation, the mutation is causing or contributing to the 
disorder. Interestingly, 5 (31%) of the 16 hot zone mutations in 
essential genes are already considered to be causal (KCNQ2, 
NOTCH2, GNAO1, and two individuals with a DYNC1H1 de 
novo  mutation; Supplementary Table S6 online). An additional 
seven are among genes with an existing OMIM or PubMed dis-
ease association with a less consistent clinical phenotypic over-
lap (DCTN1, BIN1, GRIN1, GRIN2B, COL4A1, MYO5A, and 
HUWE1). Finally, four mutations occur in genes that are strong 
genetic candidates with no existing (OMIM or PubMed) literature 
support for germ-line disease association (SLC9A1, HNRNPU, 
CELSR3, and EWSR1) (Supplementary Table S7 online). In the 
case of HNRNPU, recent studies identified de novo mutations in 
patients with epileptic encephalopathy,25,26 showing a partially 
overlapping phenotype with our patient.
DIsCUssION
In this study of 119 trios, we diagnosed 29 patients through 
WES, which is in accordance with other recent studies 
(Supplementary Table S6 online).1–4 In another 21 (17.6%) 
patients, we identified strong candidate genes based on com-
paring the properties of de novo qualifying mutations seen in 
cases to those of a collection of control trios (Supplementary 
Table S7 online). Among the unresolved trios, our inspection 
further identified candidate genes. Some trios had a qualifying 
genotype in an OMIM disease gene (Supplementary Table S4 
online), but they did not meet all the criteria described in 
“determination of genetic diagnosis.” Four trios had qualifying 
genes of interest that are not currently OMIM disease-associ-
ated genes (Supplementary Table S5 online).
Importantly, we successfully identified the genetic diag-
noses for two trios that were negative in our pilot study2 (see 
Materials and Methods). The first patient (trio N8) had an 
inherited hemizygous missense mutation in ATRX. This vari-
ant was not identified in the original analysis, in which align-
ment was to an older version of the human reference genome 
(GRCh36) and variant calling was performed using SAMtools. 
In the other patient (trio N12), we found a de novo stop gain in 
SRCAP; however, literature supporting a genetic diagnosis of 
Floating-Harbor syndrome (OMIM 136140) emerged after our 
original paper was submitted.2,27 These two examples empha-
size the value of reinterpreting clinical exomes on a regular 
basis to leverage the latest advances in medical literature and 
bioinformatics.
A solid diagnosis often has value for patients and families 
even when no new treatments result from the diagnosis. In a 
minority of cases, however, the correct diagnosis can improve 
patient management. The potential effectiveness of such gen-
otype-driven treatments is often deducible from the assayed 
biological consequence of the disease-causing mutation and 
known mechanisms of action of candidate drugs, and is further 
testable from the behavior of mutant proteins in in vitro assays 
in the presence or absence of the candidate drugs.22,23 It is also 
important to emphasize that unlike retigabine, a recently mar-
keted anticonvulsant for which the potential utility in treating 
KCNQ2-associated epileptic encephalopathy might be better 
appreciated, quinidine was not considered as a possible therapy 
for refractory seizures and would never have been tried in a 
patient without knowledge of the KCNT1 genotype. Similarly, 
the genetic diagnoses for patients affected with metabolic dis-
orders, with extensive yet uninformative metabolic workups, 
guided active clinical management (e.g., diet interventions for 
trio 24 and trio 26) that clearly benefitted the patients.
We found that 15 (13%) of the 119 interpreted trios achieved 
a genetic diagnosis based on having the same variant as those 
previously reported in patients with similar phenotypes. This 
could indicate low allelic heterogeneity among some of the dis-
ease-causing genes. As an example, for each of these 15 genes we 
considered the “opportunity” to have identified an overlapping 
pathogenic variant based on the collection of OMIM (http://
www.omim.org/), ClinVar,28 and HGMD29 reported pathogenic 
variants. We found the range to be 5–235 unique “pathogenic” 
variants per gene, or 0.02–2.79% of the possible single-nucleo-
tide substitution events after accounting for gene size. Among 
the 15 genes for which we identified the same variant in our 
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Figure 1 Hot zone bioinformatic signatures of de novo mutations. Among (a) controls and (b) cases who had at least one protein-coding de novo 
mutation identified, the gene-level (Residual Variation Intolerance Score (RVIS) genic intolerance percentile) and variant-level (PolyPhen-2) scores are plotted in 
two-dimensional space. Black circles in (b) are used for trios achieving a genetic diagnosis via the plotted de novo mutation. Blue diamonds represent de novo 
mutations among trios that have at least one de novo mutation but are currently unresolved by a de novo or inherited mutation. In (a) and (b) the hot zone is 
the shaded region corresponding to PolyPhen-2 (x-axis) ≥0.95 and RVIS (y-axis) ≤0.25. Of the 337 control de novo mutations, 44 (13.1%) occur in the hot zone 
as compared with 29 (41.4%) of 70 de novo mutations observed among cases (Fisher’s exact test, P = 2.3 × 10−7). This indicates that among the cases there is 
an excess of 20 (69%) de novo mutations in the hot zone. To further illustrate the difference between the two populations (cases = red; controls = blue), (c) 
a histogram shows the distribution of Euclidean distances to the most damaging coordinate (PolyPhen-2 = 1 and RVIS = 0) for de novo mutations plotted in 
(a) and (b). It is strikingly clear that (b) de novo mutations identified among patients ascertained for severe undiagnosed genetic conditions are drawn from 
a distribution that is significantly closer in Euclidean distance to the most damaging coordinate than are (a) de novo mutations ascertained from a control 
population (Mann–Whitney U-test, P = 6.3 × 10−7). Linear regression lines were generated for both populations. Population-level representations (d) and (e) 
of hot zone de novo mutation incidence among the two groups. Red silhouettes represent carriers of de novo hot zone mutations. For (e) cases, 29 of 103 
(28.2%) patients ascertained for an undiagnosed genetic condition, without an inherited genetic diagnosis, had a hot zone de novo mutation as compared 
with (d) controls, for which only 44 of 728 (6.0%) sequenced control trios had a hot zone de novo mutation (Fisher’s exact test, P = 3.0 × 10−10; 79% excess 
observations among cases). Moreover, adding in the layer of information regarding essential gene status (red silhouette with a blue asterisk) further pinpointed 
toward putative pathogenic mutations because among the control population only 1.9% had a hot zone de novo mutation occurring in an essential gene. 
This is compared with the 15.5% of cases (Fisher’s exact test, P = 3.4 × 10−8; 88% excess observations among cases).
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patient as in a previously reported case, SRCAP, KCNT1, and 
NOTCH2 (with 6, 11, and 22 reported variants, respectively) 
occupy the (apparently) lower end of the allelic heterogene-
ity spectrum with less than 0.1% of possible single-nucleotide 
substitutions in those genes currently listed as “pathogenic” for 
a similar disorder. One hypothesis for this interesting pattern 
of restricted allelic heterogeneity is that some disease-caus-
ing mutations more frequently arise from specific mutagenic 
mechanisms. Alternatively, it is possible that disease-causing 
mutations are restrictively distributed in genes because they can 
only disrupt biological function in limited ways or would oth-
erwise be nonviable.30 With more diagnostic WES data being 
generated, we expect a better delineation and understanding of 
the allelic heterogeneity of disease-associated genes, with sin-
gle-gene/disease resolution.
It is important to note that there is a difference between per-
fect controls—ethnically matched and screened for personal 
and family history of any relevant illness—and controls of con-
venience, such as the those provided by the EVS (http://evs.
gs.washington.edu/EVS/). The number of candidate mutations 
in the Sheba cohort was higher than that in the Duke cohort 
(Supplementary Table S3 online), and this reflects the benefits 
of having an ethnically matched control population for com-
parison. The EVS includes subjects selected for specific dis-
eases such as early-onset heart disease and stroke, as well as for 
extreme phenotypes such as very high or low cholesterol. This 
must be borne in mind when using controls of convenience for 
screening out candidate variants. One illustrative example of 
this is the patient in trio 66 with a homozygous DPYD geno-
type (c.1905+1G>A) that has been reported to cause dihydro-
pyrimidine dehydrogenase (DPD) deficiency (OMIM 274270), 
an autosomal-recessive disorder of pyrimidine metabolism.31 
Our patient had failure to thrive, global developmental delay, 
and high urine uracil levels, all consistent with DPD defi-
ciency. However, we also found a homozygous genotype in 1 
of 3,027 internal controls not known to have DPD deficiency. 
Examination of the literature shows that DPD deficiency is 
characterized by a highly variable phenotype, and some indi-
viduals with known pathogenic genotypes can be asymptom-
atic.32 This fact, together with the observation that the mutation 
has already been reported among unrelated patients with DPD 
deficiency,31 strongly supports the pathogenic nature of the 
genotype in our patient despite the occurrence of the genotype 
in a control.
Another example is the patient in trio 46, who was found 
to have a de novo nonsense mutation in ASXL1 (p.Arg404Ter, 
also a ClinVar pathogenic variant).28 This same mutation was 
previously reported in another patient with Bohring–Opitz 
syndrome.33 Our (Caucasian) patient had overlapping clinical 
features with Bohring–Opitz syndrome, including growth fail-
ure, developmental delay, microcephaly, strabismus, hypotonia, 
and seizures; therefore, the de novo ASXL1 nonsense muta-
tion is highly likely to explain the clinical presentations in our 
patient. However, this same nonsense mutation (p.Arg404Ter) 
is observed in two (presumably unrelated) EVS subjects (both of 
African-American ancestry) who are very unlikely to be affected 
with Bohring–Opitz syndrome. Because Bohring–Opitz syn-
drome is an early-onset severe malformation syndrome and its 
causal mutations are presumably highly penetrant, the presence 
of p.Arg404Ter in two African-American EVS subjects leads us 
to consider this Sanger-validated de novo nonsense mutation 
as a very good candidate rather than a “genetic diagnosis deter-
mined.” Further studies are required to elucidate the relevance 
of ASXL1 loss-of-function variants observed in control popula-
tion databases.
It is also important to bear in mind quality control differ-
ences when using controls sequenced elsewhere. For example, 
the patient of trio 19 (of Middle Eastern origin) is homozygous 
for a frameshift mutation in TECPR2, which causes autosomal-
recessive spastic paraplegia-49 (SPG49; OMIM 615031).34 The 
patient had overlapping manifestations with SPG49, including 
severe hypotonia, gastroesophageal reflux disease, areflexia, 
intellectual disability, and breathing abnormalities; however, 
this patient did not have any qualifying genotypes. Given the 
strong clinical evidence for SPG49, the patient’s treating clini-
cian requested that TECPR2 be screened more liberally than 
the qualifying genotype criteria. As a result, we identified a 
homozygous genotype (p.Leu440ArgfsTer19) that has not been 
previously reported in SPG49 patients. Among our 9,530 con-
trols, homozygosity of the same frameshift variant was found 
in one EVS subject (a European American). Because the EVS 
European-American genotypic distribution deviated from 
Hardy–Weinberg equilibrium (A1A1 = 1/A1R = 5/RR = 3,861, 
P = 0.0027),35 we asked the Exome Sequencing Project directly 
about this EVS homozygous genotype and were informed that 
the homozygous indel genotype was likely to be heterozygous 
and mistakenly called as homozygous because of the low EVS 
sequencing coverage at this locus (Qian Yi, personal communi-
cation). We report this observation of misgenotyping to advo-
cate for the careful evaluation of putatively pathogenic variants 
based on all lines of available evidence. We note that as part 
of this evaluation, we always find it useful to check Hardy–
Weinberg equilibrium in control populations as a warning of 
the possibility of genotyping errors.
We were able to identify the DPYD and ASXL1 genotypes 
(Supplementary Table S6 online) by slightly relaxing the cri-
teria to allow up to two control individuals to have the same 
genotype only when that exact genotype has been reported as 
pathogenic (Supplementary Method 1.1 online). We also note 
that such relaxation of the rules to define “qualifying status” will 
become increasingly important as the sample size used as refer-
ence controls increases.
The use of standing human variation to evaluate genic intol-
erance is emerging as a critical tool in the interpretation of 
patient genomes.12,36,37 We first introduced our “hot zone” bio-
informatic signature in the work of Petrovski et al.,12 in which 
we integrated gene- and variant-level predictions of pathoge-
nicity to prioritize de novo mutations. Comparing the de novo 
hot zone mutations in cases versus controls represents a novel 
tool to understand the genetics of the rare diseases as a whole 
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and also on an individual basis. For example, we found clear 
evidence for a statistically significant enrichment of de novo 
hot zone mutations in rare disease exomes (69% excess; P = 
2.3 × 10−7). Among the genes with a de novo hot zone muta-
tion, some occur in diagnostic Mendelian disease genes and 
others are not disease-associated. This does not mean that all 
de novo hot zone mutations are pathogenic, but rather that it is 
clear that we see an enrichment of de novo hot zone mutations 
when ascertaining for severe rare diseases such as those studied 
here, and thus this collection of hot zone de novo mutations 
will harbor some real pathogenic variants. Using additional 
information, such as essential gene status, we note that among 
the general population an individual will rarely have a hot zone 
de novo mutation within an “essential” gene (1.9% of individu-
als, based on 728 control trios), yet we see the rate among our 
patients to be 15.5% (88% excess; P = 3.4 × 10–8). Taken together, 
these clear patterns from the entire collection of different rare 
diseases not only demonstrate the existence of risk factors but 
also provide valuable information for localizing pathogenic 
mutations in individuals. The genes carrying such variants can 
then be shared with clinical and research centers so that other 
similar patients with mutations in these genes might be identi-
fied and the pathogenicity of the gene might be confirmed.
Conclusion
Despite the increasing clinical use of WES, many of the pre-
requisites for a successful diagnosis are currently best realized 
in the research setting. This includes careful consideration 
of methods to evaluate the pathogenicity of variants. As we 
showed here, there will be exceptions that require careful 
interpretation. Furthermore, given the rapid pace of new gene 
discovery, it is essential to appreciate the need to dynamically 
reanalyze patient exomes. Finally, it is clear that deployment of 
bioinformatic prioritization tools provides important pointers 
toward apparent phenotype expansion of known genes (seven 
potential examples reported here), as well as pointers toward 
novel disease genes (four potential examples reported here). 
All these highlight the important role of research geneticists in 
implementing diagnostic WES and ultimately call for the col-
laborative efforts of scientists and clinicians to fully realize the 
discovery and translational potential of WES.
SUPPLEMENTARY MATERIAL
Supplementary material is linked to the online version of the paper 
at http://www.nature.com/gim
ACKNOWLEDGMENTS
We appreciate all the patients, their parents, the clinical research 
coordinators, and the referring physicians for participating in 
this study. We thank B. Krueger, J. Bridgers, J. Keebler, Z. Ren, 
and Q. Wang for bioinformatics support. We thank K. Cronin, 
S. Shaltz, A. Richards, and N. Walley for excellent technical sup-
port. The authors thank the National Heart, Lung, and Blood 
Institute Grand Opportunity (GO) Exome Sequencing Project 
and its ongoing studies that produced and provided exome vari-
ant calls for comparison: the Lung GO Sequencing Project (HL-
102923); the WHI Sequencing Project (HL-102924); the Broad 
GO Sequencing Project (HL-102925); the Seattle GO Sequencing 
Project (HL-102926); and the Heart GO Sequencing Project (HL-
103010). S.P. is a National Health and Medical Research Coun-
cil CJ Martin Fellow. We acknowledge the following individuals 
for the contributions of control samples: W.B. Gallentine, E.L. 
Heinzen, A.M. Husain, K.N. Linney, M.A. Mikati, R.A. Radtke, 
and S.R. Sinha; J.P. McEvoy, J. Silver, and M. Silver; D.H. Murdock 
and The MURDOCK Study Community Registry and Biorepository; 
G. Cavalleri, N. Delanty, and C. Depondt; J. Burke, C. Hulette, 
and K. Welsh-Bohmer; J. Milner; J. Hoover-Fong, N.L. Sobreira, 
and D. Valle; E.J. Holtzman; W.L. Lowe; P. Lugar; S.M. Palmer; 
Z. Farfel, A. Poduri; M. Hauser; D. Marchuk; D. Koltai Attix, O. 
Chiba-Falek; E.T. Cirulli, V. Dixon, and J. McEvoy; K. Schmader, 
S. McDonald, H.K. White, M. Yanamadala, and the Carol Woods 
and Crosdaile Retirement Communities; R. Gbadegesin and M. 
Winn; D. Daskalakis; Q. Zhao; A. Holden, and E. Behr; R. Brown; 
and S. Kerns and H. Oster. The collection of control samples was 
funded in part by Bryan ADRC NIA P30 AG028377, the Ellison 
Medical Foundation New Scholar award AG-NS-0441-08, an 
award from SAIC-Frederick (M11-074), funding from Biogen Idec, 
NIMH awards RC2MH089915, R01MH097971, R01MH099216, 
and K01MH098126, the Epi4K Gene Discovery in Epilepsy study 
(NINDS U01-NS077303), the Epilepsy Genome/Phenome Project 
(EPGP - NINDS U01-NS053998), and the Center for HIV/AIDS 
Vaccine Immunology (“CHAVI”) under a grant from the National 
Institute of Allergy and Infectious Diseases, National Institutes of 
Health (UO1AIO67854). E.K.R is funded by a predoctoral grant 
from the Epilepsy Foundation and Jo Rae Wright Fellowship for 
outstanding women in science (Duke University). Additional con-
trol samples were obtained from dbGaP at http://www.ncbi.nlm.
nih.gov/gap through accession number phs000473. Samples used 
for data analysis were provided by the Swedish Cohort Collection 
supported by the NIMH grant R01MH077139, the Sylvan C. Her-
man Foundation, the Stanley Medical Research Institute, and the 
Swedish Research Council (grants 2009–4959 and 2011–4659). 
Support for the exome sequencing was provided by the NIMH 
Grand Opportunity grant RCMH089905, the Sylvan C. Herman 
Foundation, a grant from the Stanley Medical Research Institute, 
and multiple gifts to the Stanley Center for Psychiatric Research at 
the Broad Institute of MIT and Harvard.
DISCLOSURE
Partial funding for this study was provided by UCB Celltech, 
including salary support for D.B.G., X.Z., P.X., E.K.R., K.S., R.C.S., 
Y.-H.J, and V.S. D.M. is an employee of UCB. The other authors 
declare no conflict of interest.
REFERENCES
 1. Yang Y, Muzny DM, Reid JG, et al. Clinical whole-exome sequencing for the 
diagnosis of mendelian disorders. N Engl J Med 2013;369:1502–1511.
 2. Need AC, Shashi V, Hitomi Y, et al. Clinical application of exome sequencing in 
undiagnosed genetic conditions. J Med Genet 2012;49:353–361.
 3. Dixon-Salazar TJ, Silhavy JL, Udpa N, et al. Exome sequencing can improve 
diagnosis and alter patient management. Sci Transl Med 2012;4:138ra78.
 Volume 17  |  Number 10  |  October 2015  |  GeNeTICs in MeDICINe
781
Whole-exome sequencing in undiagnosed genetic diseases  |  ZHU et al Original research article
 4. de Ligt J, Willemsen MH, van Bon BW, et al. Diagnostic exome sequencing in 
persons with severe intellectual disability. N Engl J Med 2012;367:1921–1929.
 5. Enns GM, Shashi V, Bainbridge M, et al.; FORGE Canada Consortium. Mutations 
in NGLY1 cause an inherited disorder of the endoplasmic reticulum-associated 
degradation pathway. Genet Med 2014;16:751–758.
 6. Might M, Wilsey M. The shifting model in clinical diagnostics: how next-
generation sequencing and families are altering the way rare diseases are 
discovered, studied, and treated. Genet Med 2014;16:736–737.
 7. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler 
transform. Bioinformatics 2009;25:1754–1760.
 8. DePristo MA, Banks E, Poplin R, et al. A framework for variation discovery 
and genotyping using next-generation DNA sequencing data. Nat Genet 
2011;43:491–498.
 9. Cingolani P, Platts A, Wang le L, et al. A program for annotating and predicting 
the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of 
Drosophila melanogaster strain w1118; iso-2; iso-3. Fly (Austin) 2012;6:80–92.
 10. Li H, Handsaker B, Wysoker A, et al.; 1000 Genome Project Data Processing 
Subgroup. The Sequence Alignment/Map format and SAMtools. Bioinformatics 
2009;25:2078–2079.
 11. Robinson JT, Thorvaldsdóttir H, Winckler W, et al. Integrative genomics viewer. 
Nat Biotechnol 2011;29:24–26.
 12. Petrovski S, Wang Q, Heinzen EL, Allen AS, Goldstein DB. Genic intolerance to 
functional variation and the interpretation of personal genomes. PLoS Genet 
2013;9:e1003709.
 13. Adzhubei IA, Schmidt S, Peshkin L, et al. A method and server for predicting 
damaging missense mutations. Nat Methods 2010;7:248–249.
 14. Sanders SJ, Murtha MT, Gupta AR, et al. De novo mutations revealed by whole-
exome sequencing are strongly associated with autism. Nature 2012;485:237–
241.
 15. O’Roak BJ, Vives L, Girirajan S, et al. Sporadic autism exomes reveal a highly 
interconnected protein network of de novo mutations. Nature 2012;485:246–
250.
 16. Iossifov I, Ronemus M, Levy D, et al. De novo gene disruptions in children on the 
autistic spectrum. Neuron 2012;74:285–299.
 17. Gulsuner S, Walsh T, Watts AC, et al.; Consortium on the Genetics of 
Schizophrenia (COGS); PAARTNERS Study Group. Spatial and temporal 
mapping of de novo mutations in schizophrenia to a fetal prefrontal cortical 
network. Cell 2013;154:518–529.
 18. Xu B, Ionita-Laza I, Roos JL, et al. De novo gene mutations highlight patterns 
of genetic and neural complexity in schizophrenia. Nat Genet 2012;44:1365–
1369.
 19. Rauch A, Wieczorek D, Graf E, et al. Range of genetic mutations associated 
with severe non-syndromic sporadic intellectual disability: an exome sequencing 
study. Lancet 2012;380:1674–1682.
 20. Georgi B, Voight BF, Bućan M. From mouse to human: evolutionary genomics 
analysis of human orthologs of essential genes. PLoS Genet 2013;9:e1003484.
 21. Blake JA, Bult CJ, Eppig JT, Kadin JA, Richardson JE; Mouse Genome Database 
Group. The Mouse Genome Database: integration of and access to knowledge 
about the laboratory mouse. Nucleic Acids Res 2014;42(Database issue):D810–
D817.
 22. Orhan G, Bock M, Schepers D, et al. Dominant-negative effects of KCNQ2 
mutations are associated with epileptic encephalopathy. Ann Neurol 
2014;75:382–394.
 23. Milligan CJ, Li M, Gazina EV, et al. KCNT1 gain of function in 2 epilepsy 
phenotypes is reversed by quinidine. Ann Neurol 2014;75:581–590.
 24. Zhu X, Need AC, Petrovski S, Goldstein DB. One gene, many neuropsychiatric 
disorders: lessons from Mendelian diseases. Nat Neurosci 2014;17:773–781.
 25. Epi4K Consortium; Epilepsy Phenome/Genome Project; De novo mutations in 
epileptic encephalopathies. Nature 2013;501:217–221.
 26. Du X, An Y, Yu L, et al. A genomic copy number variant analysis implicates 
the MBD5 and HNRNPU genes in Chinese children with infantile spasms and 
expands the clinical spectrum of 2q23.1 deletion. BMC Med Genet 2014;15:62.
 27. Hood RL, Lines MA, Nikkel SM, et al.; FORGE Canada Consortium. Mutations in 
SRCAP, encoding SNF2-related CREBBP activator protein, cause Floating-Harbor 
syndrome. Am J Hum Genet 2012;90:308–313.
 28. Landrum MJ, Lee JM, Riley GR, et al. ClinVar: public archive of relationships 
among sequence variation and human phenotype. Nucleic Acids Res 
2014;42(Database issue):D980–D985.
 29. Stenson PD, Ball EV, Mort M, et al. Human Gene Mutation Database (HGMD): 
2003 update. Hum Mutat 2003;21:577–581.
 30. Goh KI, Cusick ME, Valle D, Childs B, Vidal M, Barabási AL. The human disease 
network. Proc Natl Acad Sci USA 2007;104:8685–8690.
 31. Vreken P, Van Kuilenburg AB, Meinsma R, et al. A point mutation in an invariant 
splice donor site leads to exon skipping in two unrelated Dutch patients with 
dihydropyrimidine dehydrogenase deficiency. J Inherit Metab Dis 1996;19:645–
654.
 32. Van Kuilenburg AB, Vreken P, Abeling NG, et al. Genotype and phenotype 
in patients with dihydropyrimidine dehydrogenase deficiency. Hum Genet 
1999;104:1–9.
 33. Hoischen A, van Bon BW, Rodríguez-Santiago B, et al. De novo nonsense 
mutations in ASXL1 cause Bohring-Opitz syndrome. Nat Genet 2011;43:729–
731.
 34. Oz-Levi D, Ben-Zeev B, Ruzzo EK, et al. Mutation in TECPR2 reveals a role for 
autophagy in hereditary spastic paraparesis. Am J Hum Genet 2012;91:1065–
1072.
 35. Wigginton JE, Cutler DJ, Abecasis GR. A note on exact tests of Hardy-Weinberg 
equilibrium. Am J Hum Genet 2005;76:887–893.
 36. Pan S, Caleshu CA, Dunn KE, et al. Cardiac structural and sarcomere genes 
associated with cardiomyopathy exhibit marked intolerance of genetic 
variation. Circ Cardiovasc Genet 2012;5:602–610.
 37. Samocha KE, Robinson EB, Sanders SJ, et al. A framework for the interpretation 
of de novo mutation in human disease. Nat Genet 2014;46:944–950.
 38. Davydov EV, Goode DL, Sirota M, Cooper GM, Sidow A, Batzoglou S. Identifying 
a high fraction of the human genome to be under selective constraint using 
GERP++. PLoS Comput Biol 2010;6:e1001025.
 39. Ng PC, Henikoff S. SIFT: Predicting amino acid changes that affect protein 
function. Nucleic Acids Res 2003;31:3812–3814.
 40. Kircher M, Witten DM, Jain P, O’Roak BJ, Cooper GM, Shendure J. A general 
framework for estimating the relative pathogenicity of human genetic variants. 
Nat Genet 2014;46:310–315.
  This work is licensed under a Creative Commons 
Attribution-NonCommercial-NoDerivs 3.0 
Unported License. The images or other third party material 
in this article are included in the article’s Creative Commons 
license, unless indicated otherwise in the credit line; if the 
material is not included under the Creative Commons license, 
users will need to obtain permission from the license holder 
to reproduce the material. To view a copy of this license, visit 
http://creativecommons.org/licenses/by-nc-nd/3.0/
GeNeTICs in MeDICINe  |  Volume 17  |  Number 10  |  October 2015
